SynthesisFrontiers in microbiology2024
Global prevalence of mutation in the
Synthesis in Frontiers in microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of colistin resistance in clinicalFuture microbiology · 2025Pooled it
- Genomic evidence of convergence of multidrug resistance and enhanced virulence in carbapenem- and colistin-resistantMicrobiology spectrum · 2026Article
- Hybrid plasmids: genetic diversity and hypervirulent phenotype ofFrontiers in microbiology · 2026Article
- Molecular characterization of colistin resistance in carbapenem-resistantMicrobiology spectrum · 2025Article
- Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producingAntimicrobial agents and chemotherapy · 2025Article
- Functional diversity and molecular interactions of small membrane proteins in bacteria.microLife · 2025Review
- The Occurrence of Colistin Resistance in Potential Lactic Acid Bacteria of Food-Producing Animals in India.Current microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colistin is used as a last resort for managing infections caused by multidrug-resistant bacteria. However, the high emergence of colistin-resistant strains has restricted the clinical use of this antibiotic in the clinical setting. In the present study, we evaluated the global prevalence of the mutation in the Methods: Several databases, including Scopus, Medline (via PubMed), and Web of Science, were searched (until August 2023) to identify those studies that address the Results: Out of the 115 studies included in the analysis, the prevalence of Conclusion: Mutations in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.